The findings, published July 31 in Cell Press Blue, build on the team’s earlier development of the DELFI (DNA Evaluation of Fragments for Early Interception) liquid biopsy platform, which analyzes millions of fragments of cell-free DNA circulating in the bloodstream. The new research validates a previously developed liver cancer classifier in independent high-risk populations and provides new insights into the biology behind its performance. This study also advances research from March 2026, in which the researchers demonstrated that a similar genome-wide fragmentome technology could detect liver fibrosis and cirrhosis, conditions that often precede liver cancer.